Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna K Nowak

Showing results (51-60 of 251) with videos related to

Pageof 26
Sort By:
BMC Cancer|June 17, 2017
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parametersAlison M McDonnell, Alistair Cook, Bruce W S Robinson, et al.
Molecular Therapy. Methods & Clinical Development|June 7, 2021
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editingEric Alves, Shahama Taifour, Riccardo Dolcetti, et al.
Frontiers in Immunology|December 5, 2022
The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine modelPeter T Graham, Anna K Nowak, Scott M J Cornwall, et al.
Respirology Case Reports|November 2, 2020
Widespread pulmonary invasion by malignant pleural mesothelioma: an important diagnostic considerationMia MacMillan, Bapti Roy, Sally McLaren, et al.
Frontiers in Oncology|August 15, 2022
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of actionCaitlin M Tilsed, Scott A Fisher, Anna K Nowak, et al.
Neuro-Oncology Practice|December 29, 2025
Healthcare professionals' perspectives on barriers and facilitators to managing brain tumor-related personality and behavior changesEmma McDougall, Haryana M Dhillon, Lauren J Breen, et al.
International Reviews of Immunology|July 19, 2012
The use of agonistic anti-CD40 therapy in treatments for cancerAndrea Khong, Delia J Nelson, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitorsTarek M Meniawy, Richard A Lake, Alison M McDonnell, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Experimental and Theoretical Mechanistic Study on the Thermal Decomposition of 3,3-diphenyl-4-(trichloromethyl)-5-nitropyrazolineKarolina Kula, Agnieszka Kącka-Zych, Agnieszka Łapczuk-Krygier, et al.
Journal of Medical Imaging and Radiation Oncology|October 29, 2023
The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort studyIsaac J May, Anna K Nowak, Roslyn J Francis, et al.
Pageof 26

Showing results (51-60 of 251) with videos related to

Sort By:
Pageof 26
BMC Cancer|June 17, 2017
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parametersAlison M McDonnell, Alistair Cook, Bruce W S Robinson, et al.
Molecular Therapy. Methods & Clinical Development|June 7, 2021
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editingEric Alves, Shahama Taifour, Riccardo Dolcetti, et al.
Frontiers in Immunology|December 5, 2022
The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine modelPeter T Graham, Anna K Nowak, Scott M J Cornwall, et al.
Respirology Case Reports|November 2, 2020
Widespread pulmonary invasion by malignant pleural mesothelioma: an important diagnostic considerationMia MacMillan, Bapti Roy, Sally McLaren, et al.
Frontiers in Oncology|August 15, 2022
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of actionCaitlin M Tilsed, Scott A Fisher, Anna K Nowak, et al.
Neuro-Oncology Practice|December 29, 2025
Healthcare professionals' perspectives on barriers and facilitators to managing brain tumor-related personality and behavior changesEmma McDougall, Haryana M Dhillon, Lauren J Breen, et al.
International Reviews of Immunology|July 19, 2012
The use of agonistic anti-CD40 therapy in treatments for cancerAndrea Khong, Delia J Nelson, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitorsTarek M Meniawy, Richard A Lake, Alison M McDonnell, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Experimental and Theoretical Mechanistic Study on the Thermal Decomposition of 3,3-diphenyl-4-(trichloromethyl)-5-nitropyrazolineKarolina Kula, Agnieszka Kącka-Zych, Agnieszka Łapczuk-Krygier, et al.
Journal of Medical Imaging and Radiation Oncology|October 29, 2023
The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort studyIsaac J May, Anna K Nowak, Roslyn J Francis, et al.
Pageof 26